"The promoter, AstraZeneca Pharmaceuticals AB Sweden has decided a voluntary non-repayable financial grant of nearly $22.5 million to 26.5 million over the three years (FY14-FY16) under a subvention agreement," AstraZeneca Pharma India said in a filing to the BSE.
AstraZeneca Pharmaceuticals AB would be provide the first tranche of $14 million (Rs 74 crore) to the Indian firm in the current financial year, it added.
Meanwhile, the AstraZenaca Pharma India management today presented a comprehensive business plan to the company's board for returning to sustainable profitability.
As part of the strategy, the company plans to commence operations at the new tablet facility, the company said.
Further the company wants to further strengthen its brand presence and also increase the effectiveness of its sales force, it added.
Shares of AstraZeneca today closed at Rs 839.15 on the BSE, up 5.43 per cent from their previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app